argenx SE

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:35:15 20/06/2025 BST			5-day change	1st Jan Change
471.10 ^EUR	-0.44%		-6.27%	-21.48%

06-20	Sector Update: Health Care Stocks Softer in Afternoon Trading	MT
06-20	Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	CI

Argenx, Zai Lab Win Chinese Nod for Injectable Formula of Autoimmune Disorder Drug

Published on 16/07/2024 at 09:51, updated on 16/07/2024 at 09:59

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about argenx SE

Sector Update: Health Care Stocks Softer in Afternoon Trading	06-20	MT
Argenx SE Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy	06-20	CI
Argenx Receives European Commission Approval for Monotherapy to Treat Neuromuscular Disorder	06-20	MT
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	06-16	MT
Argenx Says Vyvgart Improved Muscle Strength in Phase 2 Myositis Trial	06-11	MT
Argenx SE Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease	06-11	CI
Argenx Presents New Data Highlighting Phase 2 Results In Myositis And Sjogren'S Disease	06-10	RE
Argenx SE Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08:40 AM	06-10
Scholar Rock Holding Corporation Announces Appointment of Rebecca Mcleod as Chief Brand Officer	06-02	CI
European Equities Close Lower in Wednesday Trading; French GDP Edges Higher	05-28	MT
Argenx Set to See Further Growth Due to Vyvgart Momentum, Pipeline Expansion, Wedbush Says	05-28	MT
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	05-21	MT
Argenx SE Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04:20 PM	05-14
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading	05-13	MT
Baird Upgrades argenx to Outperform From Neutral, Price Target is $680	05-13	MT
Donald Trump deals another blow to Big Pharma	05-12
European Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	05-08	MT
Sector Update: Health Care Stocks Decline Pre-Bell Thursday	05-08	MT
Argenx SE, Q1 2025 Earnings Call, May 08, 2025	05-08
Argenx Reports Q1 Earnings, Higher Operating Income; Shares Down Pre-Bell	05-08	MT
U.S. Futures, European Stocks Rise	05-08	DJ
Immunology Company argenx Swings to Profit in Q1; Net Sales Rise	05-08	MT
Argenx Q1 Total Operating Income At $807.37 Mln	05-08	RE
Argenx SE Reports Earnings Results for the First Quarter Ended March 31, 2025	05-08	CI
On the stockmarket, the pharmaceutical industry is wary of FDA's new strongman	05-07

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,599

Sector

Biotechnology & Medical Research

Calendar

07-31 - Q2 2025 Earnings Release

More about the company